Cameron Turtle, MD, PhD, is a hematology oncologist at SCCA, a UW associate professor of Oncology and Medicine, and an associate member at Fred Hutchinson Cancer Research Center. He serves as an attending physician on the Hematopoietic Cell Transplant Service and the Immunotherapy Service at Seattle Cancer Care Alliance, Fred Hutch’s clinical care partner, and the UW Medical Center. Patients with hematologic malignancies are faced with a multitude of treatment options. Dr. Turtle aims to carefully consider the wishes and goals his patients have for therapy and use this information to design appropriate strategies.
Dr. Turtle studies how immune T cells can be engineered to fight hematologic malignancies, such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia and acute myeloid leukemia. His laboratory in the Clinical Research Division at Fred Hutch is focused on understanding the characteristics of distinct subsets of human CD8+ T cells, their potential utility for tumor immunotherapy, and their role in immune reconstitution after blood stem cell transplantation.
Dr. Turtle’s lab has extensive expertise in the genetic modification and analysis of T cells, and he leads several investigator-initiated clinical trials of CD19-targeted chimeric antigen receptor (CAR)-modified T-cell therapies for patients with B-cell malignancies.